Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Epcoritamab in NHL - Incidence and Management of CRS

GRACE

T. Phillips

Update on Cellular Therapy in Lymphoma

Total Health

B. Randolph

Current Management of Peripheral T-Cell Lymphoma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

C. Poh

Basics of T-Cell Lymphoma: Diagnosis and Treatment

MyCancerHaven

R. Vij, N. Mehta-Shah

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Indy Hematology Review

T. Phillips

Novel Combinations in Indolent Lymphoma

SOHO 2023 Eleventh Annual Meeting

P. Strati

Novel Therapeutics for T-Cell Lymphoma: Navigating Regulatory Pitfal…

UChicago Medicine

S. Iyer

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon